1. Home
  2. GRNT vs EVO Comparison

GRNT vs EVO Comparison

Compare GRNT & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Granite Ridge Resources Inc.

GRNT

Granite Ridge Resources Inc.

N/A

Current Price

$6.34

Market Cap

667.4M

Sector

Finance

ML Signal

N/A

Logo Evotec SE

EVO

Evotec SE

N/A

Current Price

$1.59

Market Cap

568.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GRNT
EVO
Founded
2013
1993
Country
United States
Germany
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
667.4M
568.6M
IPO Year
2022
2007

Fundamental Metrics

Financial Performance
Metric
GRNT
EVO
Price
$6.34
$1.59
Analyst Decision
Buy
Buy
Analyst Count
5
3
Target Price
★ $8.60
$4.48
AVG Volume (30 Days)
★ 1.5M
65.9K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
★ 6.98%
N/A
EPS Growth
★ 28.57
N/A
EPS
N/A
★ N/A
Revenue
★ $450,306,000.00
N/A
Revenue This Year
$51.35
N/A
Revenue Next Year
$6.79
$18.90
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 18.49
N/A
52 Week Low
$4.18
$1.33
52 Week High
$6.54
$3.87

Technical Indicators

Market Signals
Indicator
GRNT
EVO
Relative Strength Index (RSI) 66.62 48.34
Support Level $4.67 $1.50
Resistance Level N/A $1.61
Average True Range (ATR) 0.33 0.06
MACD 0.09 0.01
Stochastic Oscillator 90.98 28.13

Price Performance

Historical Comparison
GRNT
EVO

About GRNT Granite Ridge Resources Inc.

Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: